Market closed
MannKind/$MNKD
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About MannKind
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
Ticker
$MNKD
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
413
Website
MannKind Metrics
BasicAdvanced
$1.9B
Market cap
86.40
P/E ratio
$0.08
EPS
1.30
Beta
-
Dividend rate
Price and volume
Market cap
$1.9B
Beta
1.3
52-week high
$7.39
52-week low
$3.17
Average daily volume
3.2M
Financial strength
Current ratio
4.545
Quick ratio
3.839
Long term debt to equity
-159.239
Total debt to equity
-165.16
Interest coverage (TTM)
1.60%
Management effectiveness
Return on assets (TTM)
9.12%
Return on equity (TTM)
-9.34%
Valuation
Price to earnings (TTM)
86.4
Price to revenue (TTM)
6.974
Price to book
-9
Price to tangible book (TTM)
-8.7
Price to free cash flow (TTM)
64.536
Growth
Revenue change (TTM)
51.35%
Earnings per share change (TTM)
-166.03%
3-year revenue growth (CAGR)
48.64%
3-year earnings per share growth (CAGR)
-37.41%
What the Analysts think about MannKind
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for MannKind stock.
MannKind Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
MannKind Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
MannKind News
AllArticlesVideos
MannKind Corporation: A Speculative Buy On IPF And Diabetes Markets
Seeking Alpha·5 days ago
MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)
GlobeNewsWire·6 days ago
CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for MannKind stock?
MannKind (MNKD) has a market cap of $1.9B as of December 22, 2024.
What is the P/E ratio for MannKind stock?
The price to earnings (P/E) ratio for MannKind (MNKD) stock is 86.4 as of December 22, 2024.
Does MannKind stock pay dividends?
No, MannKind (MNKD) stock does not pay dividends to its shareholders as of December 22, 2024.
When is the next MannKind dividend payment date?
MannKind (MNKD) stock does not pay dividends to its shareholders.
What is the beta indicator for MannKind?
MannKind (MNKD) has a beta rating of 1.3. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.